Advancing precision radiotherapy through novel cancer targeting strategies

This project aims to explore and potentiate molecular radiotherapy of cancer, where cancer-targeting molecules are equipped with radionuclides to enable cancer-specific imaging and/or radiotherapy.

The aims for the present project are:Tailored Radiopharmaceutical Development:We aim to pioneer the development and optimization of molecular radiotherapy agents, targeting key biomarkers such as CD44v6, CEA, and NK1R.

In particular, the project will expand into  target selection, modeling and selection strategies as well as modifications in radionuclide load, radiochemistry and administration strategies will be explored.

Enhancing Radiotherapy Effects:Our objective is to synergistically enhance the efficacy of radiotherapy through the strategic combination of molecular radiotherapy with novel drugs that modulate radiation response and interact with the immune system.

By harnessing innovative approaches like p53 modulation, HSP90 inhibition, and checkpoint inhibition, we aim to unleash the full potential of radiotherapy while mitigating collateral damage to healthy tissues.We are uniquely positioned to conduct this research, with several advanced model systems and instruments in place, exciting preliminary results, a unique network and solid experience in the field.

In the long term, we aim to advance precision cancer radiotherapy, enabling more effective treatments and contributing to improved outcomes for cancer patients.